Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Dagny Holle-Lee, MD, PhD, Essen University Hospital, Essen, Germany, discusses the results of three randomized, double-blind, placebo-controlled Phase III studies evaluating the early efficacy of galcanezumab in older patients with migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).